Latest filings (excl ownership)
424B3
Prospectus supplement
1 May 24
EFFECT
Notice of effectiveness
30 Apr 24
EFFECT
Notice of effectiveness
29 Apr 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
S-3
Shelf registration
9 Apr 24
8-K
Departure of Directors or Certain Officers
5 Apr 24
8-K
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides
11 Mar 24
8-K
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
7 Mar 24
POS AM
Prospectus update (post-effective amendment)
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
27 Feb 24
POSASR
Automatic shelf registration (post-effective amendment)
13 Feb 24
S-8
Registration of securities for employees
2 Jan 24
8-K
Cost Associated with Exit or Disposal Activities
7 Dec 23
8-K
Departure of Directors or Certain Officers
22 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress
9 Nov 23
8-K
VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16
6 Nov 23
8-K
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis
10 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress
10 Aug 23
8-K
Entry into a Material Definitive Agreement
25 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
PRE 14A
Preliminary proxy
13 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress
23 Mar 23
8-K
Regulation FD Disclosure
26 Jan 23
8-K
Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors
12 Jan 23
S-8
Registration of securities for employees
5 Jan 23
EFFECT
Notice of effectiveness
23 Dec 22
POS AM
Prospectus update (post-effective amendment)
20 Dec 22
8-K
Entry into a Material Definitive Agreement
20 Dec 22
S-3ASR
Automatic shelf registration
20 Dec 22
Latest ownership filings
4
Somu Subramaniam
16 Apr 24
4
Change in insider ownership
16 Apr 24
SC 13G
Flynn James E
4 Apr 24
4
Christopher W Krueger
3 Apr 24
4
John Nuss
3 Apr 24
4
Raju Mohan
3 Apr 24
4
Martin Auster
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
4
Christopher W Krueger
29 Mar 24
4
Martin Auster
29 Mar 24
4
Raju Mohan
29 Mar 24
4
John Nuss
29 Mar 24
SC 13G
Cormorant Asset Management, LP
21 Mar 24
SC 13D/A
NSV Investments I, L.P.
13 Mar 24
SC 13D/A
NSV Investments I, L.P.
8 Mar 24
SC 13G
Point72 Asset Management, L.P.
23 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G
TANG CAPITAL PARTNERS LP
29 Jan 24
SC 13G
BlackRock Inc.
29 Jan 24
4
William Richard White
23 Jan 24
4
Somu Subramaniam
23 Jan 24
4
ALLISON HULME
23 Jan 24
4
Onaiza Cadoret-Manier
23 Jan 24
4
Sheila Gujrathi
23 Jan 24
4
Martin Auster
3 Jan 24
4
Raju Mohan
3 Jan 24
4
John Nuss
3 Jan 24
4
Christopher W Krueger
3 Jan 24
4
John Nuss
21 Dec 23
4
Christopher W Krueger
21 Dec 23
4
Raju Mohan
21 Dec 23
144
Notice of proposed sale of securities
20 Dec 23
144
Notice of proposed sale of securities
20 Dec 23
144
Notice of proposed sale of securities
20 Dec 23
4
Raju Mohan
19 Dec 23
4
John Nuss
19 Dec 23